- Hydresia(TM) G2 approved by leading European authority on natural/
organic certification -
TSX symbol: SBS
CALGARY, Oct. 6 /CNW/ - Botaneco Specialty Ingredients Inc. (Botaneco), a
subsidiary of SemBioSys Genetics Inc. (SemBioSys), today announced that its
second generation oleosome product, Hydresia(TM) G2, has been authorized by
ECOCERT(R) as an approved raw material, complying with the standards for
ecological and organic cosmetics. ECOCERT(R) is one of the largest organic
control and certification organizations in the world and conducts inspections
in over 80 countries. The company's primary focus is food and food products,
cosmetics, detergents, perfumes, and textiles.
"Botaneco is dedicated to manufacturing its all-natural products to
comply with the highest natural production standards while eliminating the use
of chemicals and synthetics," said Andrew Baum, president and CEO of
Botaneco's parent company, SemBioSys. "The ECOCERT(R) authorization validates
our product and production process with the most internationally recognized
symbol for natural and organic raw materials."
Hydresia(TM) G2 is a cold-process emulsifying system comprised of
oleosomes, naturally occurring oil reservoirs derived from safflower seeds.
Oleosomes are nature's warehouse, or storage facility, for the emollient oils,
antioxidants and natural moisture barriers that serve to keep the skin soft,
supple and young looking. Using a proprietary non-solvent aqueous extraction
process, these oleosomes are isolated from the seed fully intact, and when
used in skin care applications can provide lasting protection to the skin.
Hydresia(TM) G2 is a natural, renewable replacement for hydrocarbon derived
petrolatum, mineral oil and non-ionic surfactants.
About Botaneco Specialty Ingredients Inc.
Botaneco is the global developer and marketer of innovative
oleosome-based ingredients to the personal care and OTC topical markets. As a
technologically driven provider of high performance, proprietary
oleosome-based ingredients, Botaneco is committed to developing innovative
ingredients that offer multifunctional, tangible and documented benefits to
both formulators and consumers. Botaneco's head office and manufacturing
facility is located in Calgary, Canada and its satellite office in Bensalem,
PA. More information is available and can be accessed at www.botaneco.ca.
About SemBioSys Genetics Inc.
With headquarters in Calgary, Alberta, SemBioSys Genetics Inc. is a
biotechnology company developing protein-based pharmaceuticals for metabolic
and cardiovascular diseases. The Company's lead pharmaceutical candidates are
recombinant human insulin to serve the rapidly expanding global diabetes
market and Apo AI, a next generation cardiovascular drug. In addition to its
pharmaceutical products, SemBioSys is developing a series of
non-pharmaceutical products addressing animal and aquaculture health,
nutritional oils and human topical markets. More information is available and
can be accessed at www.sembiosys.com.
ECOCERT(R) is a control and certification organization, whose activities
are governed accordingly by the public authorities and legislation. Based in
Europe, ECOCERT(R) conducts inspections in over 80 countries and is accredited
for structure and procedures by COFRAC (French committee for accreditation),
in accordance with guide standard ISO 65 (EN 45011), which requires
independence, competence and impartiality.
This press release contains certain forward-looking statements,
including, without limitation, statements containing the words "believe",
"may", "plan", "will", "estimate", "continue", "anticipate", "intend",
"expect" and other similar expressions which constitute "forward-looking
information" within the meaning of applicable Canadian securities laws.
Forward-looking statements reflect the Company's current expectation and
assumptions, and are subject to a number of risks and uncertainties that could
cause actual results to differ materially from those anticipated. These
forward-looking statements involve risks and uncertainties including, but not
limited to, changing market conditions, the successful and timely completion
of clinical studies, the establishment of corporate alliances, the impact of
competitive products and pricing, new product development, uncertainties
related to the regulatory approval process and other risks detailed from
time-to-time in the Company's ongoing filings with the Canadian securities
regulatory authorities which filings can be found at www.sedar.com. Given
these risks and uncertainties, readers are cautioned not to place undue
reliance on such forward-looking statements. The Company undertakes no
obligation to publicly update or revise any forward-looking statements either
as a result of new information, future events or otherwise, except as required
by applicable Canadian securities laws.
For further information:
For further information: Botaneco Specialty Ingredients Inc., Andrew
Baum, President and Chief Executive Officer, Phone: (403) 717-8767, E-mail: